Celldex Therapeutics (CLDX) has an average broker rating of 1.89, which is interpreted as a Buy, as rated by 9 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Celldex Therapeutics (CLDX) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $24 and the lowest price target forecast is $3. The average forecast of all the analysts is $8.63 and the expected standard deviation is $6.89.
For the current week, the company shares have a recommendation consensus of Buy.
Celldex Therapeutics (NASDAQ:CLDX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.54 and $4.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.66. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.66, notching a gain of 2.42% for the day. The total traded volume was 1,273,624 . The stock had closed at $4.55 on the previous day.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.